Skip to Content

Proposed Rule

Generic Drug Issues; Request for Comments

Document Details

Information about this document as published in the Federal Register.

Document Statistics
Document page views are updated periodically throughout the day and are cumulative counts for this document including its time on Public Inspection. Counts are subject to sampling, reprocessing and revision (up or down) throughout the day.
Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble


Food and Drug Administration, HHS.


Request for comments.


The Food and Drug Administration (FDA) is requesting public comments on whether additional regulatory actions should be taken concerning the approval of abbreviated new drug applications (ANDAs). The agency is asking for comments because of recent statutory changes. The agency is not proposing any regulatory changes in this notice. The purpose of this notice is to identify a number of issues that the agency would like interested persons to address and to give interested persons an opportunity to submit comments on possible actions.


Submit written or electronic comments by May 3, 2004.


Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 200857. Submit electronic comments to​dockets/​ecomments.

Start Further Info


Elaine Tseng, Office of Regulatory Policy (HFD-7), Food and Drug Administration, 5515 Security Lane, Rockville, MD 20852, 301-594-2041.

End Further Info End Preamble Start Supplemental Information


I. Background

On December 8, 2003, President Bush signed into law the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) (Public Law 108-173). Title XI of MMA made changes to section 505(a), (b), and (j) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 505(a), (b), and (j). In particular, Title XI of MMA made changes to the approval procedures for ANDAs.

FDA is considering what additional regulatory steps, if any, are warranted in light of the statutory changes. The specific portions of the statute for which FDA seeks comment are Title XI of MMA's provisions concerning the 30-month stay of effectiveness period, 180-day exclusivity, and bioavailability and bioequivalence. FDA seeks comments identifying issues contained in the relevant portions of Title XI of MMA, along with any suggestions for how to resolve those issues. FDA will consider these comments in assessing what regulatory actions might be appropriate.

II. Comments

Interested persons may submit to the Division of Dockets Management (see ADDRESSES) written of electronic comment regarding this document. Submit a single copy of electronic comments or two paper copies of any mailed comments, except that individuals may submit one paper copy. Comments are to be identified with the docket number found in brackets at the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.

Start Signature

Dated: February 27, 2004.

Jeffrey Shuren,

Assistant Commissioner for Policy.

End Signature End Supplemental Information

[FR Doc. 04-4775 Filed 3-1-04; 8:45 am]